CD70 is a novel therapeutic target for EGFR mutant NSCLC with acquired, EMT-associated EGFR TKI resistance

被引：0

作者：

Nilsson, Monique B. ^{[1
]}

Yang, Yan ^{[1
]}

Patel, Sonia ^{[1
]}

Heeke, Simon ^{[1
]}

Le, Xiuning ^{[1
]}

Aruguman, Thiru ^{[1
]}

Robichaux, Jacqulyne ^{[1
]}

Yu, Xiaoxing ^{[1
]}

Poteete, Alissa ^{[1
]}

Ren, Xiaoyang ^{[1
]}

Diao, Lixia ^{[1
]}

Shen, Li ^{[1
]}

Wang, Qi ^{[1
]}

Zhang, Fahao ^{[1
]}

Clemente, Leticia Campos ^{[1
]}

Soto, Luisa Solis ^{[1
]}

Shi, Chunhua ^{[1
]}

Tran, Hai ^{[1
]}

Bock, Jason ^{[1
]}

Wang, Jing ^{[1
]}

Wistuba, Ignacio I. ^{[1
]}

Minna, John D. ^{[2
]}

Heymach, John V. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Univ Texas SouthWestern Med Ctr, Dallas, TX USA

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1827

引用

页数：1

共 50 条

[1] CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Nilsson, Monique B.
Yang, Yan
Heeke, Simon
Patel, Sonia A.
Poteete, Alissa
Udagawa, Hibiki
Elamin, Yasir Y.
Moran, Cesar A.
Kashima, Yukie
Arumugam, Thiruvengadam
Yu, Xiaoxing
Ren, Xiaoyang
Diao, Lixia
Shen, Li
Wang, Qi
Zhang, Minying
Robichaux, Jacqulyne P.
Shi, Chunhua
Pfeil, Allyson N.
Tran, Hai
Gibbons, Don L.
Bock, Jason
Wang, Jing
Minna, John D.
Kobayashi, Susumu S.
Le, Xiuning
Heymach, John V.
CANCER CELL, 2023, 41 (02) : 340 - +
[2] EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
Laurila, Niina
Koivunen, Jussi P.
MEDICAL ONCOLOGY, 2015, 32 (07)
[3] EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
Niina Laurila
Jussi P. Koivunen
Medical Oncology, 2015, 32
[4] EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
Zhu, Xuan
Chen, Lijie
Liu, Ling
Niu, Xing
FRONTIERS IN ONCOLOGY, 2019, 9
[5] Acquired resistance in NSCLC with EGFR mutation treated with TKI's
Lueers, A.
Hallas, C.
Henke, R. -P
Falk, M.
Tiemann, M.
Griesinger, F.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 6 - 6
[6] IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Patel, Sonia A.
Nilsson, Monique B.
Yang, Yan
Le, Xiuning
Tran, Hai T.
Elamin, Yasir Y.
Yu, Xiaoxing
Zhang, Fahao
Poteete, Alissa
Ren, Xiaoyang
Shen, Li
Wang, Jing
Moghaddam, Seyed Javad
Cascone, Tina
Curran, Michael
Gibbons, Don L.
Heymach, John, V
CLINICAL CANCER RESEARCH, 2023, 29 (07) : 1292 - 1304
[7] Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC
Freydman, Jessica
Henshaw, Lynnette
Patel, Jasmine V.
Smith, Claire E.
Everett, Peter C.
ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 503 - 504
[8] BCG020, a novel bispecific antibody targeting EGFR and CD70, is effective against EGFR and CD70 high expressed tumors
Yang, Yongfei
Sun, Xiaoxia
Li, Ziyan
Yan, Yue
Xu, Linpeng
Wu, Xiaoxue
Du, Luheng
Zhu, Ying
Guo, Chaoshe
An, W. Frank
CANCER RESEARCH, 2024, 84 (06)
[9] Investigation of Acquired Resistance for EGFR-TKI Plus Bevacizumab as 1st Line Treatment in Patients with EGFR Sensitive Mutant NSCLC
Zhang, Y.
Zeng, L.
Yang, N.
Jiang, T.
Zhou, C.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S363 - S364
[10] Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
Liam, C. K.
Ahmad, A. Rozila
Hsia, T.
Li, J. Y.
Le, X.
Heymach, J.
Yang, J. C.
Soo, R.
Zhang, Y.
Kim, S.
Shin, S. W.
Johne, A.
Karachaliou, N.
Bruns, R.
Ellers-Lenz, B.
Wu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1118 - S1119

← 1 2 3 4 5 →